Licenseable Technologies

Globe and Mail and Global News Toronto cover early-stage Bio Printer technology

U of T Ph.D. student Lian Leng demonstrates how the Bio Printer prototype creates new skin cells. — U of T Ph.D. student **Lian Leng** demonstrates how the Bio Printer prototype creates new skin cells. Screen shot courtesy of Global News Toronto.

An early-stage technology that may revolutionize the way burn victims are treated is generating considerable buzz in Toronto media this week.

Globe and Mail reporter Robert Everett-Green wrote about the joint University of Toronto and Sunnybrook Health Sciences Centre project January 20 in “A 3-D machine that prints skin? How burn care could be revolutionized.”

Health reporter Beatrice Politi also covered the Bio Printer project for Global News Toronto January 21. Her video segment includes an interview with PhD student Lian Leng and a look at the existing Bio Printer prototype.

Biotechnology Focus’ December issue covers MaRS Innovation projects and partnerships

January 10, 2013
Susanne Staer
Industry Partners

Stem Cell Therapeutics Corp.

MaRS Innovation’s (MI) projects and partnerships earned three separate article mentions in the December 2012 issue of Biotechnology Focus, including:

MI and UHN’s partnership with Stem Cell Therapeutics was covered in the magazine’s Dealmakers subsection. Read the write-up on the Biotechnology Focus website.
Cellax, a licensable technology that may produce a nanotechonology-based cancer drug, was highlighted in the magazine’s Business Corner section (read the write-up). Cellax is a joint project between MI and the Ontario Institute for Cancer Research.
MaRS Innovation’s collaboration with the Centre for Commercialization of Regenerative Medicine was highlighted in a feature article, “Efforts to commercialize regenerative medicine in Canada growing steadily.”

MI Inventors Poon and Rahnama Pitch EMTech 2012 (Videos Online)

November 26, 2012
Susanne Staer
Awards

Being named to the MIT Technology Review's 35 Inventors Under 35 list is a prestigious honour, but one of its best perks is the subsequent invitation to attend the Emerging…

OICR and MaRS Innovation announce funding to develop Cellax™, a nanotechnology-based cancer drug

TORONTO, ON (November 13, 2012) — The Ontario Institute for Cancer Research (OICR) and MaRS Innovation (MI) today announced $1.5 million in funding from OICR over three years to further develop Cellax™, a nanoparticle drug that could offer an alternative to chemotherapy with fewer side effects.

“Cellax is promising because it provides a more targeted strategy for treating tumours, killing tumour cells while minimizing the effect on healthy tissue,” said Dr. Rima Al-awar, director, OICR’s Medicinal Chemistry Platform. “OICR is proud to invest in a technology that has such potential to one day improve quality of life for cancer patients.”

Cellax, invented by Dr. Shyh-Dar Li and his research team in OICR’s Medicinal Chemistry Platform group, is a drug-polymer conjugate based on Dr. Li’s proprietary NanoCMC™ technology. These polymers self-assemble into defined nanoparticles and, when injected, selectively accumulate in tumours. Because of this property, the drug is released where it is most needed, increasing therapeutic benefits and reducing the side effects associated with conventional chemotherapy.

Stem Cell Therapeutics, UHN and MaRS Innovation Announce Novel, Clinical-Stage, Cancer Stem Cell Program Agreement

Stem Cell Therapeutics Corp.

Stem Cell Therapeutics Corp. (TSX VENTURE:SSS), a life sciences company developing stem cell-related technologies, today announced the signing of an agreement with University Health Network (UHN), through its commercialization agent MaRS Innovation (MI), both of Toronto.

The agreement provides Stem Cell Therapeutics (“SCT”) with an option to an exclusive world-wide license to an innovative cancer stem cell program.

This agreement produced a license for a UHN technology on April 17, 2013.

ClevrU partners with Schulich School of Business professors to target online education market

MaRS Innovation and York University’s commercialization office support new partnership

Students in China interact with the ClevrU platform. Photo courtesy of ClevrU Inc.

In the age of ITunes, videotaping lectures or converting existing textbooks into e-books won’t make you the market leader in online education.

Thanks to a new partnership between ClevrU, and NewMindsets Inc., facilitated by MaRS Innovation and York University’s commercialization office, Canadian technology and content promises to establish the second-generation online learning standard for millions of students worldwide.

Los Angeles Times covers Dr. Gregory Czarnota’s cancer therapy technology

The Los Angeles Times featured Dr. Gregory Czarnota’s research in their Science Now section on July 10, 2012, which reports on discoveries from the world of science and medicine (update: the article is no longer available online).

Czarnota, a researcher at the Sunnybrook Health Sciences Centre, is working with MaRS Innovation to license his patented technology: radiosensitization of tumour cells using a combination of microbubbles and targeted, high-intensity, focused ultrasound.

MaRS Innovation brokers deal between sanofi-aventis and Sunnybrook Health Sciences Centre

February 15, 2011
Susanne Staer
Industry Partners

Bridgewater, NJ and Toronto, ON- February 15, 2011 - Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) and Sunnybrook Health Sciences Centre (Toronto, Canada) announced that they have entered into a research…

CAMH researcher’s leading-edge therapy targets brain chemistry of addiction

December 17, 2009
Susanne Staer
Centre for Addiction and Mental Health (CAMH)

CAMH and MaRS Innovation partner on innovative approach to nicotine addiction

TORONTO (Dec. 17, 2009) — Grappling with nicotine addiction is never easy, but a new drug therapy – developed by Dr. Fang Liu at the Centre for Addiction and Mental Health (CAMH) – brings promise to one of our great public health challenges.

The experimental medication in development at Dr. Liu’s lab targets the brain chemistry associated with addiction by disrupting a specific receptor-receptor interaction.

Proof-of-concept data demonstrate that this therapy decreases addictive behavior associated with nicotine and alcohol in preclinical models.

MaRS Innovation selects University of Toronto’s Diabetic Wound Healing Technology as second commercialization opportunity

TORONTO (June 30, 2009) – MaRS Innovation (MI) and the University of Toronto (U of T) are pleased to announce that they have entered into an agreement to collaboratively commercialize a novel sustained release formulation of nitric oxide (NO) for applications in wound healing, including diabetic ulcers.

“There are 300 million diabetics worldwide, of which some 15 per cent develop troublesome foot ulcers. This wound healing technology is extremely exciting, making it an early commercialization opportunity that MaRS Innovation has identified as being a potential win for some 45 million diabetics globally,” said Dr. Raphael (Rafi) Hofstein, president and CEO of MaRS Innovation.

Globe and Mail and Global News Toronto cover early-stage Bio Printer technology

Biotechnology Focus’ December issue covers MaRS Innovation projects and partnerships

MI Inventors Poon and Rahnama Pitch EMTech 2012 (Videos Online)

OICR and MaRS Innovation announce funding to develop Cellax™, a nanotechnology-based cancer drug

Stem Cell Therapeutics, UHN and MaRS Innovation Announce Novel, Clinical-Stage, Cancer Stem Cell Program Agreement

ClevrU partners with Schulich School of Business professors to target online education market

MaRS Innovation and York University’s commercialization office support new partnership

Los Angeles Times covers Dr. Gregory Czarnota’s cancer therapy technology

MaRS Innovation brokers deal between sanofi-aventis and Sunnybrook Health Sciences Centre

CAMH researcher’s leading-edge therapy targets brain chemistry of addiction

CAMH and MaRS Innovation partner on innovative approach to nicotine addiction

MaRS Innovation selects University of Toronto’s Diabetic Wound Healing Technology as second commercialization opportunity

Quick Links

Contact Us